As a clinical approach for AMD gene therapy, primary retinal pigment epithelial (RPE) and iris pigment epithelial (IPE) cells have been subjected to genetic modification in order to highly express pigment epithelia derived factor (PEDF) – the natural antagonist of VEGF. Here, VEGFA is linked to age-related macular degeneration.